Abstract
We reported a 66-year-old male patient with advanced gastric cancer accompanied by multiple liver metastasis, who responded to combination chemotherapy using UFT, CDDP and etoposide. The patient was administered three courses of 600 mg/body UFT po daily, 50 mg/body CDDP iv and 50 mg/body etoposide iv on days 1 and 8 every 4 weeks. As a result, both the primary and metastatic tumors decreased remarkably in size. Adverse reactions were leukocytopenia (Grade 2), thrombocytopenia (Grade 1) and nausea (Grade 1). he is alive 16 months after the beginning of therapy in a condition of partial response (PR). This combination therapy seemed to be effective for advanced gastric cancer.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / secondary*
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Drug Administration Schedule
-
Drug Combinations
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Humans
-
Injections, Intravenous
-
Lentinan / administration & dosage
-
Leukopenia / chemically induced
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary*
-
Male
-
Nausea / chemically induced
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology*
-
Tegafur / administration & dosage
-
Tegafur / adverse effects
-
Thrombocytopenia / chemically induced
-
Uracil / administration & dosage
-
Uracil / adverse effects
Substances
-
Drug Combinations
-
UFT(R) drug
-
Tegafur
-
Lentinan
-
Uracil
-
Etoposide
-
Cisplatin